To include your compound in the COVID-19 Resource Center, submit it here.

U.S. and China clear Phase III of DB102 to treat DLBCL

Denovo Biopharma LLC (San Diego, Calif.) said FDA and China FDA approved an IND to begin the Phase III ENGINE trial of enzastaurin (DB102) to treat diffuse

Read the full 274 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE